Kinase Inhibitor Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Choosing the most effective TKIs for individual patients with chronic myeloid leukemia requires decision making based on efficacy data, agent safety profiles, and patient characteristics, according to Michael Deininger, MD.

United statesMichael deiningerSociety of hematologic oncologyMeeting of the society hematologic oncologyVersiti blood research instituteBristol myers squibbAnnual societyHematologic oncologyRational choiceAnnual meetingSociety hematologic oncologyKinase inhibitor trialChronic myeloid leukemiaYear updateOptic trialDose optimization study